



Índice por temas

B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- CO 26 DIFFERENTIATING TRANSTHYRETIN CARDIAC AMYLOIDOSIS AMONG LEFT VENTRICULAR HYPERTROPHY PHENOTYPES: THE ROLE OF RIGHT AND LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN
- CO 68 CAN MY ECHO WORK AS A CRYSTALBALL? - ECHOCARDIOGRAPHIC PARAMETERS PREDICTING RESIDUAL PULMONARY HYPERTENSION AFTER PULMONARY ENDARTERECTOMY
- PO 79 PERFORMANCE OF GUIDELINE-SUGGESTED RISK SCORES FOR INFECTIVE ENDOCARDITIS IN A REAL-WORLD COHORT
- PO 120 THE SPECTRUM OF HYPERTROPHIC CARDIOMYOPATHIES - WHERE IS FABRY?
- PO 121 ECHOCARDIOGRAPHIC DIFFERENTIATION OF CARDIAC AMYLOIDOSIS SUBTYPES
- PO 174 UNVEILING THE IMPACT OF ANTHRACYCLINE CHEMOTHERAPY ON RESTING AND EXERCISE ECHOCARDIOGRAPHY
- PO 175 EVALUATION OF MYOCARDIAL WORK DURING EXERCISE ECHOCARDIOGRAPHY IN A HEALTHY POPULATION
- PO 176 THE ATHLETE'S HEART: INSIGHTS INTO ATRIAL AND VENTRICULAR PERFORMANCE
- PO 177 THE INFLUENCE OF RESTING, EXERCISE-INDUCED HYPERTENSION AND CARDIAC REMODELING ON MYOCARDIAL WORK INDICES
- PO 178 LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION DURING DOBUTAMINE STRESS TEST ECHOCARDIOGRAPHY - PREDICTORS AND PROGNOSTIC IMPACT
- PO 192 PREDICTORS OF MORTALITY IN A LEAD-RELATED TRICUSPID REGURGITATION POPULATION - IS THE RIGHT VENTRICLE THE KEY?
- PO 252 MYOCARDIAL WORK BY SPECKLE-TRACKING ECHOCARDIOGRAPHY IN PACEMAKER CARRIERS ACCORDING TO PACING SITE
- PO 254 IMPACT OF CARDIOVASCULAR RISK FACTORS IN MYOCARDIAL WORK
- PO 255 OPTIMIZED MEDICAL THERAPY ENHANCES LEFT ATRIAL STRAIN IN HFREF PATIENTS: A NOVEL PROGNOSTIC INDICATOR
- PO 256 LEFT ATRIUM STRAIN ANALYSIS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A PREDICTIVE TOOL FOR ATRIAL FIBRILLATION
- PO 257 ASSESSMENT OF LEFT VENTRICULAR MYOCARDIAL WORK PERFORMANCE IN PATIENTS WITH ESSENTIAL HYPERTENSION
- PO 261 MEASURING INTEGRATED BACKSCATTER IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 262 IS RELATIVE AORTIC VALVE LOAD DETERMINANT OF LEFT VENTRICULAR REMODELING IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR SURGICAL VALVE REPLACEMENT?

B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- CO 61 DIAGNÓSTICO DE DOENÇA CORONÁRIA ESTÁVEL POR ANGIO TOMOGRAFIA COMPUTADORIZADA COMO EXAME DE PRIMEIRA LINHA: ANÁLISE DE CUSTOS NUM CENTRO DE RESPONSABILIDADE INTEGRADA
- CO 70 INCREMENTAL PROGNOSTIC VALUE OF CT-DERIVED EXTRACELLULAR VOLUME IN SEVERE AORTIC STENOSIS
- CO 88 EPICARDIAL ADIPOSE TISSUE PLAYS AN ADDITIONAL ROLE IN CARDIOVASCULAR RISK ASSESSMENT TOGETHER WITH CORONARY ARTERY CALCIUM SCORE
- CO 99 DYNAMIC CT PERFUSION TO IDENTIFY HEMODYNAMICALLY SIGNIFICANT CORONARY ARTERY DISEASE: PRELIMINARY RESULTS OF A "ONE-STOP-SHOP" APPROACH

- PO 263 ACCURACY OF COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR THE EXCLUSION OF CORONARY ARTERY DISEASE BEFORE TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 264 TOTAL FIBROCALCIFIC BURDEN OF THE AORTIC VALVE IN PATIENTS WITH AORTIC STENOSIS - ASSESSMENT BY A NEW CT METHOD AND COMPARATIVE PERFORMANCE WITH CALCIUM SCORING
- PO 265 PROGNOSTIC VALUE OF CARDIAC COMPUTED TOMOGRAPHY PARAMETERS TO PREDICT PRE-INTERVENTION OUTCOMES IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 266 AORTIC CALCIUM SCORE AND TAVR: INSIGHTS INTO PROCEDURAL COMPLICATIONS AND DEVICE SELECTION
- PO 315 IS LIPOPROTEIN(A) A PREDICTOR OF COMPUTED TOMOGRAPHY ANGIOGRAPHY FINDINGS? A RETROSPECTIVE STUDY IN A TERTIARY CENTER
- PO 316 IMPACT OF CORONARY CALCIFICATION ON LIPID-LOWERING THERAPY DECISIONS FOLLOWING CORONARY COMPUTED TOMOGRAPHY WITH NON-OBSTRUCTIVE CORONARY DISEASE OR NON-DIAGNOSTIC RESULT

B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE

- CO 67 SUBCLINICAL FOCAL FIBROSIS AND ABNORMAL LEFT VENTRICULAR STRAIN IN PATIENTS WITH SARCOIDOSIS WITHOUT CLINICAL EVIDENCE OF CARDIAC DISEASE
- CO 79 THE INFLUENCE OF GENOTYPE ON THE PHENOTYPE AND PROGNOSIS OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY:
- CO 80 "RING-LIKE" LATE GADOLINIUM ENHANCEMENT: EXPLORING PATTERNS AND OUTCOMES
- CO 86 PROGNOSTIC VALUE OF STRESS PERFUSION CARDIAC MAGNETIC RESONANCE: REAL-WORLD EVIDENCE FROM A LARGE PORTUGUESE COHORT
- CO 87 REDUCED MRI-BASED RIGHT-TO-LEFT VENTRICULAR BLOOD POOL T2 RATIO PREDICTS ADVERSE EVENTS AND IMPAIRED CARDIOPULMONARY FUNCTION IN HEART FAILURE PATIENTS
- CO 98 MACHINE LEARNING ALGORITHMS FOR PREDICTING ARRHYTHMIC EVENTS IN HYPERTROPHIC CARDIOMYOPATHY: LIMITED ENHANCEMENT BEYOND LATE GADOLINIUM ENHANCEMENT
- PO 122 GENOTYPE-PHENOTYPE CORRELATIONS WITH LATE GADOLINIUM ENHANCEMENT PATTERNS IN PRIMARY CARDIOMYOPATHY
- PO 123 IMPACT OF NOVEL MAXIMAL WALL THICKNESS ADJUSTMENTS ON ARRHYTHMIC EVENT PREDICTION IN HYPERTROPHIC CARDIOMYOPATHY
- PO 124 MYOCARDIAL STRAIN CHANGES AS ASSESSED BY FEATURE TRACKING CMR IN PATIENTS WITH ACUTE MYOCARDITIS AND PRESERVED EJECTION FRACTION. IMPACT ON PROGNOSIS
- PO 125 CARDIAC MAGNETIC RESONANCE FINDINGS IN FABRY DISEASE
- PO 317 ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE - THE NEXT STEP IN PREDICT ATRIAL FIBRILLATION?
- PO 318 INCREMENTAL VALUE OF CARDIAC MRI OVER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF AORTIC REGURGITATION
- PO 319 FIBROSIS ASSESSMENT IN PATIENTS WITH FREQUENT VENTRICULAR EXTRASYSTOLES AND NORMAL ECHOCARDIOGRAMS: INSIGHTS FROM CARDIAC MRI
- PO 320 ATRIAL PARAMETERS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE AND ITS ASSOCIATION WITH ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING

- CO 62 ASSESSMENT OF MYOCARDIAL BLOOD FLOW CHANGES USING [¹³N]NH₃ PET-CT IN CHRONIC TOTAL CORONARY OCCLUSION PATIENTS UNDERGOING PCI
- PO 105 THE SODIUM FLUORIDE AORTIC GRADIENT: INSIGHTS FROM THE ROPPET-NAF STUDY

B. IMAGING -> 03. IMAGING -> 03.6 CROSS-MODALITY AND MULTI-MODALITY IMAGING TOPICS

- PO 258 EXPLORING RV-ARTERIAL COUPLING: COMPARING CMR-DERIVED RV STRAIN AND ECHO-BASED MYOCARDIAL WORK INDICES IN PRE-CAPILLARY PULMONARY HYPERTENSION

B. IMAGING -> 03. IMAGING -> 03.7 IMAGING - OTHER

- PO 267** ROLE OF PREOPERATIVE CAROTID DUPLEX ULTRASOUND IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR INTERVENTION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.3 ARRHYTHMIAS, GENERAL - DIAGNOSTIC METHODS

- CO 59** VALIDATION OF IMAGELESS ELECTROCARDIOGRAPHIC IMAGING FOR ACCESSORY PATHWAY LOCALISATION IN WPW SYNDROME
- PO 300** BASELINE INTERVALS ON ELECTROCARDIOGRAM AS A SCREENING TOOL FOR DIAGNOSING BRUGADA SYNDROME IN FAMILY MEMBERS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.4 ARRHYTHMIAS, GENERAL - TREATMENT

- PO 377** PAEDIATRIC CATHETER ABLATION IN A TERTIARY CENTRE: CONTEMPORARY CHARACTERIZATION AND CLINICAL OUTCOMES

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 357** A SIMPLIFIED PREDICTIVE SCORE FOR ATRIAL FIBRILLATION RECURRENCE AFTER ELECTRICAL CARDIOVERSION USING ELECTROCARDIOGRAPHIC PARAMETERS: THE RECAF-SCORE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT

- CO 50** INAPPROPRIATE DIRECT ORAL ANTICOAGULANT DOSING IN ATRIAL FIBRILLATION: A PORTUGUESE SINGLE-CENTER STUDY
- CO 56** ZERO-FLUOROSCOPY ATRIAL FIBRILLATION ABLATION: INITIAL EXPERIENCE IN A SINGLE-CENTER COHORT
- CO 57** PULSED FIELD ABLATION: A NEW STANDARD FOR SINGLE-SHOT ATRIAL FIBRILLATION ABLATION
- PO 108** SEX-SPECIFIC DIFFERENCES IN ATRIAL REMODELLING AND RECURRENCE RISK AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION
- PO 279** EFFICACY, EFFICIENCY AND SAFETY OF PULSED FIELD ABLATION IN PATIENTS WITH ATRIAL FIBRILLATION
- PO 280** RENAL DENERVATION AS AN ADJUNCT TO PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION ABLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 281** COMPARISON OF STANDARD-POWER AND VERY HIGH-POWER SHORT-DURATION PULMONARY VEIN ABLATION
- PO 282** NON-PULMONARY VEIN TRIGGERS - MAXIMIZING SUCCESS IN ATRIAL FIBRILLATION REDO PROCEDURES
- PO 283** REDUCING RECURRENCE, ENHANCING SUCCESS: THE ROLE OF SUBSTRATE MODIFICATION IN ATRIAL FIBRILLATION REDO PROCEDURES
- PO 284** HIGH-POWER ABLATION GUIDED BY ABLATION INDEX IN ATRIAL FIBRILLATION: A RETROSPECTIVE STUDY
- PO 356** REDEFINING SUCCESS IN ATRIAL FIBRILLATION - EFFICACY OF REDO ABLATION PROCEDURE AND IMPORTANCE OF LEFT ATRIAL VOLUME
- PO 358** AF RE-ABLATION: A COMPARATIVE ANALYSIS OF THE EFFICACY OF INITIAL PVI PROCEDURES
- PO 359** GENDER DIFFERENCES IN ATRIAL FIBRILLATION PATIENTS UNDERGOING CATHETER ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION

- PO 353** LEFT ATRIAL APPENDAGE OCCLUSION: RESULTS OF A LARGE LONG-TERM COHORT

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.8 ATRIAL FIBRILLATION - CLINICAL

- PO 181** DEVELOPMENT OF ATRIAL FIBRILLATION AFTER CAVOTRICUSPID ISTHMUS-DEPENDENT ATRIAL FLUTTER ABLATION: ANALYSIS OF INCIDENCE AND RISK FACTORS IN A PORTUGUESE TERTIARY CARE CENTER.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER

- PO 355** IMPACT OF DIASTOLIC DYSFUNCTION ON QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS UNDERGOING CATHETER ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.1 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - PATHOPHYSIOLOGY AND MECHANISMS

- CO 58** ELECTROPHYSIOLOGICAL CHARACTERIZATION OF TACHYCARDIA CIRCUIT AND UNDERLYING SUBSTRATE IN ATYPICAL ATRIAL FLUTTERS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.3 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - DIAGNOSTIC METHODS

- PO 375** THE EASY-WPW ALGORITHM IN PRACTICE: REAL-WORLD ACCURACY IN PREDICTING ACCESSORY PATHWAY LOCATIONS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT

- PO 351** OUTCOMES OF ATYPICAL FLUTTER ABLATION GUIDED EXCLUSIVELY BY SYSTEMATIC ANALYSIS OF HIGH-RESOLUTION MAPS (NO ENTRAINMENT MANEUVERS)
- PO 352** WILL IT BE BACK? PREDICTING RECURRENCE AFTER LEFT ATRIAL FLUTTER ABLATION
- PO 354** ADVANCEMENTS IN ATYPICAL ATRIAL FLUTTER ABLATION: IMPACT OF EVOLVING TECHNIQUES AND TECHNOLOGIES ON OUTCOMES
- PO 376** GENERAL ANAESTHESIA COMPARED TO CONSCIOUS SEDATION FOR CATHETER ABLATION OF ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA IN ADOLESCENTS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.3 SYNCOPE AND BRADYCARDIA - DIAGNOSTIC METHODS

- PO 370** SIMPLIFIED TOOL FOR PREDICTING PACEMAKER IMPLANTATION IN PATIENTS WITH BRADYCARDIC SYNCOPE UNDERGOING IMPLANTABLE LOOP RECORDER MONITORING: THE PREDICT-PPM SCORE
- PO 371** PREDICTORS OF PACEMAKER IMPLANTATION IN PATIENTS UNDERGOING IMPLANTABLE LOOP RECORDER MONITORING FOR SUSPECTED BRADYCARDIC SYNCOPE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT

- PO 369** CARDIONEUROABLATION IN PATIENTS WITH HYPERVAGOTONIA - AN EFFECTIVE SOLUTION?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.7 SYNCOPE AND BRADYCARDIA - OTHER

- PO 372** ENHANCING QUALITY OF LIFE IN REFLEX SYNCOPE PATIENTS: EFFICACY OF A STRUCTURED EDUCATIONAL PROGRAMME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT

- CO 19 EXPLORING THE SAFETY AND EFFICACY OF RENAL DENERVATION IN ELECTRICAL STORM MANAGEMENT
- CO 60 LONG-TERM OUTCOMES OF VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS PRESENTING WITH ELECTRICAL STORM
- CO 66 ECGI TO GUIDE VT ABLATION IN STRUCTURAL HEART DISEASE
- PO 297 INSIGHTS ON CARBON DIOXIDE INSUFFLATION TECHNIQUE FOR EPICARDIAL ACCESS ABLATION OF REFRACTORY ARRHYTHMIAS: SAFETY AND CLINICAL OUTCOMES
- PO 299 NONINVASIVE ELECTROCARDIOGRAPHIC MAPPING VS. CONVENTIONAL ECG ANALYSIS IN PREDICTING VENTRICULAR TACHYCARDIA ORIGIN
- PO 301 SINUS RHYTHM LATE ACTIVATION ZONES AS A TARGET FOR IMPROVING VENTRICULAR TACHYCARDIA ABLATION OUTCOMES

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.7 VENTRICULAR ARRHYTHMIAS AND SCD - OTHER

- PO 288 PRO-BNP VARIATION AS A RISK MARKER OF VENTRICULAR ARRHYTHMIAS IN CRT PATIENTS
- PO 349 ECHOCARDIOGRAPHIC PREDICTORS OF SUSTAINED VENTRICULAR TACHYARRHYTHMIAS IN PATIENTS WITH CRT-D FOR PRIMARY PREVENTION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING

- CO 21 LEFT BUNDLE BRANCH PACING AND MECHANICAL DESYNCHRONY: A REAL-WORLD PERSPECTIVE
- CO 22 LEFT BUNDLE BRANCH AREA PACING: LONGITUDINAL DATA ON PACING EFFICACY
- CO 23 ADOPTION OF AN ECHO-GUIDED AXILLARY PUNCTURE WORKFLOW IS ASSOCIATED WITH FASTER PROCEDURAL DURATION IN TRANSVENOUS PACEMAKER IMPLANTATION
- PO 67 PACEMAKER IN NONAGENARIAN AND CENTENARIAN PATIENTS: A FIVE-YEAR EXPERIENCE AT A TERTIARY CENTER
- PO 68 GENDER DIFFERENCES IN NONAGENARIANS UNDERGOING PACEMAKER IMPLANTATION
- PO 130 RIGHT BUNDLE BRANCH BLOCK AND THE RISK OF PACEMAKER IMPLANTATION AFTER TAVI: AN OBSERVATIONAL STUDY
- PO 303 FEASIBILITY, SAFETY AND MID-TERM PARAMETERS STABILIZATION OF LEFT BUNDLE BRANCH PACING: A SINGLE CENTER EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARIOVERTER / DEFIBRILLATOR

- PO 285 OUTCOMES AFTER IMPLANTATION OF SUBCUTANEOUS-IMPLANTABLE CARIOVERTER DEFIBRILLATORS (S-ICDS) FOR SECONDARY PREVENTION
- PO 286 IMPLANTATION OF EXTRAVASCULAR ICD: A SINGLE-CENTRE EXPERIENCE
- PO 287 SUBCUTANEOUS VERSUS TRANSVENOUS IMPLANTABLE CARIOVERTER-DEFIBRILLATOR THERAPY: INSIGHTS FROM REAL-WORD EVIDENCE
- PO 289 IMPLANTABLE CARIOVERTER-DEFIBRILLATOR - DO WE HAVE ALTERNATIVE PREDICTORS TO ADMINISTERED SHOCKS?
- PO 322 ARE PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY LESS DESERVING OF PRIMARY PREVENTION DEVICE IMPLANTATION?
- PO 332 LONG-TERM EFFECT OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS ON ICD AND CRT-D THERAPY OUTCOMES IN PATIENTS WITH HFREF

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY

- PO 71 ADVANCED THERAPEUTIC INTERVENTIONS IN ELDERLY HEART FAILURE: OUTCOMES OF CARDIAC RESYNCHRONIZATION THERAPY

- PO 290 CRT IN PATIENTS REQUIRING ANTIBRADYCARDIA PACING - ARE THEY GOOD RESPONDERS?
- PO 321 LONG-TERM COMPARATIVE EFFECTIVENESS OF A HEMODYNAMIC SENSOR-BASED CRT VERSUS STANDARD CRT: INSIGHTS INTO CARDIAC AND FUNCTIONAL IMPROVEMENTS
- PO 324 CARDIOPULMONARY EXERCISE TESTING TO ASSESS THE EFFECT OF CARDIAC RESYNCHRONISATION THERAPY
- PO 325 THE IMPACT OF ATRIAL FIBRILLATION IN CARDIAC RESYNCHRONISATION THERAPY'S RESPONSE
- PO 330 EVALUATING RISK SCORES FOR CRT RESPONSE AND CLINICAL OUTCOMES: FINDING THE IDEAL TOOL
- PO 331 IMPACT OF LOW HEMOGLOBIN VALUES IN CRT RESPONSE
- PO 346 CARDIAC RESYNCHRONIZATION THERAPY FOR NON-LBBB PATIENTS AND QRS MID-RANGE: WORTH IT?
- PO 347 LONG TERM CLINICAL OUTCOME AND ECHOCARDIOGRAPHIC RESPONSE OF PATIENTS SUBMITTED TO UPGRADE TO CARDIAC RESYNCHRONIZATION THERAPY
- PO 348 CARDIAC RESYNCHRONISATION THERAPY'S RESPONSE IN PATIENTS WITH NON-LBBB QRS COMPLEX MORPHOLOGY
- PO 350 EVALUATING SUPERRESPONSE IN CRT: A CLINICAL EDGE OR JUST A REMODELING EFFECT?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING

- PO 146 PREVENTION OF HEART FAILURE HOSPITALIZATION BASED ON REMOTE MONITORING AND EARLY INTERVENTION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.5 DEVICE COMPLICATIONS AND LEAD EXTRACTION

- CO 24 PREDICTORS AND PROGNOSIS OF LEAD RELATED TRICUSPID REGURGITATION
- PO 304 IS THERE AN OPTIMAL TIMING FOR DEVICE REIMPLANTATION AFTER LEAD EXTRACTION DUE TO CIED INFECTION?
- PO 305 NON-INFECTED LEAD EXTRACTIONS: A BETTER LONG-TERM SOLUTION?
- PO 307 ABSORBABLE ANTIBACTERIAL ENVELOPE ELIMINATES ADDITIONAL EXPECTED CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIONS IN HIGH-RISK PATIENTS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER

- PO 306 QRS INTERVAL AND VENTRICULAR DYSSYNCHRONY - ROLE IN LEAD-RELATED TRICUSPID REGURGITATION
- PO 308 PACING-INDUCED CARDIOMYOPATHY IN PATIENTS WITH A HIGH PERCENTAGE OF VENTRICULAR PACING: A RETROSPECTIVE STUDY
- PO 326 PREDICTORS FOR ADVERSE OUTCOMES IN ICD/CRT-D PATIENTS: INSIGHTS FROM A SINGLE-CENTER STUDY

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- CO 11 MAPPING HEART FAILURE CARE IN PORTUGAL: ACCESS, RESOURCES, AND REGIONAL INEQUITIES
- CO 12 SOCIOECONOMIC AND ETHNIC FACTORS AFFECTING HEART FAILURE TREATMENT AND PROGNOSIS: EXPLORING DISPARITIES IN CLINICAL OUTCOMES
- CO 73 PHENOTYPING HEART FAILURE WITH REDUCED EJECTION FRACTION: A MACHINE LEARNING APPROACH TO PATIENT STRATIFICATION
- PO 60 UNCOVERING PREDICTORS OF ADVERSE OUTCOMES IN HFREF AFTER ACUTE MYOCARDIAL INFARCTION
- PO 133 PORTUGUESE VERSION VALIDATION AND PREDICTIVE PERFORMANCE OF THE HEART FAILURE SYMPTOM TRACKER (HFAST) FOR 3- AND 6-MONTH HOSPITALIZATIONS
- PO 136 PERFORMANCE OF MORTALITY RISK SCORES IN ADVANCED HEART FAILURE PATIENTS: A RETROSPECTIVE COHORT STUDY
- PO 188 IMPROVEMENT OF FUNCTIONAL STATUS AND ENHANCED SURVIVAL ESTIMATES AFTER 330 LEVOSIMENDAN ADMINISTRATIONS

- PO 309 PORTUGUESE HEART FAILURE OBSERVATIONAL STUDY - MADEIRA (PORTHOS-MADEIRA): CHARACTERISTICS INDIVIDUALS WITH NT-PROBNP ELEVATION
- PO 310 PORTUGUESE HEART FAILURE OBSERVATIONAL STUDY - MADEIRA (PORTHOS-MADEIRA) PHASE 1: BASELINE CHARACTERISTICS
- PO 323 RISK STRATIFICATION IN NONISCHEMIC DILATED CARDIOMYOPATHY: THE ROLE OF T1/T2 MAPPING AND EXTRACELLULAR VOLUME

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS

- PO 72 SEGMENTAL KINETIC DISTURBANCES: A POOR PREDICTOR OF CORONARY ARTERY DISEASE IN VERY ELDERLY PATIENTS WITH HEART FAILURE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT

- CO 51 INTERMITTENT LEVOSIMENDAN AND SURVIVAL OUTCOMES IN ADVANCED HEART FAILURE: A REAL-WORLD, SINGLE-CENTRE STUDY
- CO 52 IMPACT OF FUNCTIONAL MITRAL REGURGITATION ON OUTCOMES FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY FOR HEART FAILURE
- CO 53 CRT-P VS CRT-D IN NON-ISCHEMIC CARDIOMYOPATHY: STILL A MATTER OF DEBATE
- PO 126 TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-ANALYSIS OF HOSPITALIZATION OUTCOMES IN HEART FAILURE AND SECONDARY MITRAL REGURGITATION
- PO 127 LEFT VENTRICULAR DYSFUNCTION AND TAVI - PREDICTORS OF RECOVERY AND OUTCOMES
- PO 128 PERCUTANEOUS MITRAL VALVE REPAIR VS SURGERY ON 12-MONTH MORTALITY/HOSPITALIZATIONS IN MITRAL REGURGITATION: A META-ANALYSIS OF CLINICAL TRIALS AND PROPENSITY-MATCHED COHORTS
- PO 129 A META-ANALYSIS OF QUALITY OF LIFE OUTCOMES AFTER TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION
- PO 139 IMPACT OF THE HEARTMATE 3 ON QUALITY OF LIFE IN HEART FAILURE: A STUDY USING EQ-5D-5L
- PO 187 INTERMITTENT LEVOSIMENDAN IN ADVANCED PALLIATIVE HEART FAILURE IMPROVES QUALITY OF LIFE AND REDUCES HEART FAILURE DECOMPENSATIONS: A SINGLE CENTER-EXPERIENCE
- PO 189 A REAL WORLD EXPERIENCE OF 330 LEVOSIMENDAN ADMINISTRATIONS
- PO 191 INTERMITTENT LEVOSIMENDAN THERAPY IN ADVANCED HEART FAILURE PATIENTS AWAITING HEART TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
- PO 291 BREAKING BOUNDARIES: HEMOGLOBIN, HEMATOCRIT AND HEART FAILURE - THE SGLT2 INHIBITOR CONNECTION
- PO 293 ROLE OF ORAL IRON IN HFREF AND DECREASED TRANSFERRIN SATURATION: A SECONDARY ANALYSIS OF IRONOUT-HF.
- PO 327 IMPACT OF OPTIMIZED MEDICAL THERAPY ON ICD SHOCKS AND SURVIVAL IN HEART FAILURE PATIENTS
- PO 328 TRANSFORMING HEART FAILURE CARE: THE IMPACT OF CARDIAC REHABILITATION
- PO 329 CARDIAC RESYNCHRONIZATION THERAPY IN SEVERE HEART FAILURE PATIENTS: THE ROLE OF ARNIS IN THE MODERN THERAPEUTIC LANDSCAPE
- PO 345 IMPACT OF RIGHT VENTRICULAR DYSFUNCTION IMPROVEMENT IN HEART FAILURE PATIENTS TREATED WITH CARDIAC RESYNCHRONIZATION THERAPY

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.5 CHRONIC HEART FAILURE - PREVENTION

- PO 144 CLINICAL AND BIOCHEMICAL CHARACTERISTICS ASSOCIATED WITH IMPROVED HEART FAILURE OUTCOMES FOLLOWING A TELEMONITORING PROGRAM

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL

- CO 91 EFFECTIVE REGURGITANT ORIFICE AREA AND LEFT VENTRICULAR VOLUME IMPACT ON HOSPITALIZATIONS EFFECTS OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-REGRESSION ANALYSIS
- PO 74 A NEW ERA IN CARDIO-ONCOLOGY: UPRISING HEART FAILURE THERAPIES FOR CARDIO-PERMISSIVE STRATEGIES IN CANCER THERAPY-RELATED CARDIAC DYSFUNCTION
- PO 135 A NOVEL RISK SCORE COMBINING BIOMARKERS OF HYPERVOLEMIA PREDICTS 1-YEAR OUTCOMES IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION
- PO 140 ASSESSMENT OF PALLIATIVE CARE NEEDS IN ADVANCED HEART FAILURE PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES
- PO 143 PREDICTORS OF CARDIAC ALLOGRAFT VASCULOPATHY AND DYSFUNCTION IN HEART TRANSPLANTATION: A SINGLE-CENTER STUDY
- PO 292 ELEVATED FERRITIN AS A POTENTIAL RISK MARKER FOR DISEASE SEVERITY AND PROGNOSIS IN HEART FAILURE
- PO 295 UNRAVELLING THE UGLY TRUTH ABOUT SLEEP APNEA AND ADVANCED HEART FAILURE: A PORTUGUESE REAL-WORLD SETTING
- PO 296 HYPERURICEMIA: A MARKER OF SEVERE CONGESTION AND DISEASE BURDEN IN HEART FAILURE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER

- CO 13 THE EXPERIENCE OF 253 EARLY POST DISCHARGE HEART FAILURE APPOINTMENTS: WHAT WE HAVE LEARNED
- PO 19 ASSOCIATION OF AN ATTR CARDIOMYOPATHY RISK SCORE WITH CARDIAC AND KIDNEY OUTCOMES AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE - INSIGHTS FROM CRIC
- PO 141 CAUSES AND PROGNOSTIC IMPLICATIONS OF HOSPITAL ADMISSIONS FOLLOWING SUCCESSFUL HEART TRANSPLANTATION
- PO 145 TELECONSULTATION: A TOOL TO SUPPORT PEOPLE WITH HEART FAILURE

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 134 EJECTION FRACTION IN HEART FAILURE AND INTENSIVE CARE ADMISSION: WHAT IS THE PROGNOSTIC IMPACT?
- PO 137 CLINICAL CHARACTERISTICS AND OUTCOMES OF DE NOVO VERSUS ACUTE DECOMPENSATED HEART FAILURE: ARE THEY SIMILAR?
- PO 138 HEART TRANSPLANT IN ACUTELY ILL PATIENTS: TIME ON WAITING LIST AND 1-YEAR MORTALITY
- PO 142 THE ROLE OF MULTIDISCIPLINARY HEART FAILURE OUTPATIENT CLINICS IN THE MANAGEMENT AND PROGNOSIS OF PATIENTS WITH ADVANCED HEART FAILURE

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.3 ACUTE HEART FAILURE - DIAGNOSTIC METHODS

- PO 59 PREDICTORS OF CORONARY ARTERY DISEASE IN ACUTE HEART FAILURE PATIENTS: DO THEY ALL BENEFIT FROM INVASIVE CORONARY ANGIOGRAPHY?
- PO 186 INTRARENAL VENOUS DOPPLER GUIDED DIURETIC MANAGEMENT ON HOSPITAL STAY

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.4 ACUTE HEART FAILURE- TREATMENT

- PO 131 STRATEGIC TIMING IN TEER: SURVIVAL IMPLICATIONS FOR MITRAL REGURGITATION IN HEART FAILURE
- PO 132 THE ABCDE SCORE: A SIMPLE TOOL FOR PREDICTING 3-MONTH MORTALITY IN ACUTE HEART FAILURE PATIENTS
- PO 190 OPTIMAL INITIAL FUROSEMIDE DOSING IN ACUTE HEART FAILURE: IMPACT ON HOSPITALIZATION AND 1-YEAR MORTALITY
- PO 294 PREDICTING EVENTS IN FERROPENIC ACUTE HEART FAILURE PATIENTS: THE B12 PARADOX

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC METHODS**

- CO 63** ASSOCIATION BETWEEN ABDOMINAL FAT DISTRIBUTION AND SEVERITY OF CORONARY ARTERY DISEASE: DATA FROM A LARGE COHORT OF PATIENTS SUBMITTED TO CARDIAC CT SCAN
- PO 275** EXPLORING FUNCTIONAL CORONARY DISEASE BEYOND OBSTRUCTIVE LESIONS
- PO 276** TRENDS IN PHYSIOLOGY AND CORRELATION BETWEEN IFR AND FFR IN CORONARY PHYSIOLOGICAL ASSESSMENT: A DECADE OF REAL-WORLD DATA

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT**

- PO 246** ANTI-THROMBOTIC AND GLUCOSE LOWERING THERAPY IN PATIENTS WITH DIABETES AND CORONARY ARTERY DISEASE UNDERGOING PCI. FINAL REPORT ON TWO-YEAR OUTCOMES OF THE ARTHEMIS STUDY

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.5 CORONARY ARTERY DISEASE - PREVENTION**

- CO 1** UNDERSTANDING THE UNDERPINNING OF HYPERTRIGLYCERIDEMIA AS A RISK FACTOR FOR ATHEROSCLEROSIS
- PO 51** HIGH-SENSITIVITY C-REACTIVE PROTEIN AS A PREDICTOR OF CARDIOVASCULAR EVENTS IN YOUNG PATIENTS FOLLOWING MYOCARDIAL INFARCTION.

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL**

- PO 277** CHARACTERIZATION OF PATIENTS WITH LEFT MAIN CORONARY ARTERY DISEASE IN NON-ACUTE SETTINGS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.7 NON-ATHEROSCLEROTIC CORONARY ABNORMALITIES**

- PO 364** UNROOFING SURGERY FOR ANOMALOUS AORTIC ORIGIN OF THE RIGHT CORONARY ARTERY: A SINGLE CENTRE EXPERIENCE

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- CO 89** INCREMENTAL PROGNOSTIC ROLE OF LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN AFTER ACUTE MYOCARDIAL INFARCTION
- PO 45** RETHINKING AKI RISK: BEYOND CONTRAST VOLUME IN ACUTE MYOCARDIAL INFARCTION
- PO 46** SHOCK INDEX-CREATININE CLEARANCE IN ACUTE CORONARY SYNDROME
- PO 54** LONG-TERM OUTCOMES AND RISK FACTORS IN YOUNG ADULTS WITH ACUTE CORONARY SYNDROME: A DECADE OF EXPERIENCE
- PO 55** PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER UNSTABLE ANGINA: IS IT POSSIBLE?
- PO 56** PREDICTORS OF SIGNIFICANT CORONARY ARTERY DISEASE IN A CONTEMPORARY COHORT OF UNSTABLE ANGINA PATIENTS
- PO 57** INSIGHTS INTO LEFT VENTRICULAR SYSTOLIC FUNCTION RECOVERY FOLLOWING ACUTE CORONARY SYNDROME
- PO 58** MECHANICAL COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION: CLINICAL CHARACTERISTICS AND MORTALITY TRENDS

- PO 69 CLINICAL OUTCOMES IN NONAGENARIANS UNDERGOING EMERGENT CORONARY ANGIOGRAPHY: A RETROSPECTIVE ANALYSIS
- PO 198 THE SAFETY OF EARLY DISCHARGE FOR LOW-RISK STEMI PATIENTS IDENTIFIED BY ZWOLLE RISK SCORE
- PO 199 TRENDS IN PRIMARY ANGIOPLASTY OUTCOMES: MORTALITY, PROCEDURAL ADVANCEMENTS, AND LESION TYPE EVOLUTION OVER TIME
- PO 200 ACUTE HEART FAILURE FOLLOWING ST-ELEVATION MYOCARDIAL INFARCTION: PATIENT PROFILING
- PO 201 CLINICAL PROFILE AND PREDICTORS OF 30-DAY ALL-CAUSE MORTALITY OF STEMI PATIENTS RECEIVING FIBRINOLYTIC THERAPY IN AN ULTRA-PERIPHERAL REGION
- PO 202 EFFECT OF AIR TEMPERATURE ON ACUTE MYOCARDIAL INFARCTION INCIDENCE: A STUDY IN THE CENTRE-SOUTH REGION OF PORTUGAL
- PO 209 CLINICAL FEATURES AND OUTCOMES OF TAKOTSUBO SYNDROME
- PO 251 ACUTE CORONARY SYNDROMES WITHOUT THE USUAL SUSPECTS: PREVALENCE AND CLINICAL OUTCOMES OF PATIENTS WITHOUT STANDARD MODIFIABLE RISK FACTORS (SMURF-LESS)

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS

- CO 20 CHANGING THE PARADIGM IN ACUTE CORONARY SYNDROMES: FROM STEMI VS. NSTEMI TO OMI VS. NON-OMI
- CO 72 PRELIMINARY RESULTS FROM THE EXTERNAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE MODEL FOR OCCLUSION MYOCARDIAL INFARCTION DETECTION
- PO 52 STRATIFICATION OF CHEST PAIN IN THE EMERGENCY DEPARTMENT: HOW EFFECTIVELY DO RISK SCORES PREDICT CORONARY ARTERY STENOSIS?
- PO 53 IDENTIFYING PREDICTORS OF MISCLASSIFICATION IN OCCLUSION MYOCARDIAL INFARCTION
- PO 210 HIGH-SENSITIVITY TROPONIN I PEAK IN MINOCA - A USEFUL TOOL IN THE RIGHT CLINICAL CONTEXT?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT

- CO 16 OUTCOMES AND PROCEDURAL BURDEN OF CULPRIT-ONLY VS. MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION IN CARDIOGENIC SHOCK: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
- PO 204 UNCOATING NEW STRATEGIES: DRUG-COATED BALLOONS AS A PROMISING CHOICE
- PO 207 THE PORTUGUESE PERSPECTIVE ON THE MANAGEMENT OF MINOCA PATIENTS
- PO 228 OUTCOMES OF EXTRACORPOREAL MEMBRANE OXYGENATION VS. INTRA-AORTIC BALLOON PUMP IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A RETROSPECTIVE COMPARATIVE ANALYSIS
- PO 247 TRENDS IN P2Y12 INHIBITOR USE AFTER ACUTE CORONARY SYNDROMES IN PORTUGAL: A DECADE OF INSIGHTS FROM THE PROACS REGISTRY
- PO 248 TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH STEMI TREATED WITH FIBRINOLYSIS: A RETROSPECTIVE REAL-WORLD ANALYSIS
- PO 249 COMPARATIVE IN-HOSPITAL OUTCOMES OF P2Y12 INHIBITORS FOLLOWING ACUTE CORONARY SYNDROMES: EVIDENCE FROM THE PROACS REGISTRY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.5 ACUTE CORONARY SYNDROMES - PREVENTION

- PO 48 LIPOPROTEIN A AND CARDIOVASCULAR RISK IN ACUTE MYOCARDIAL INFARCTION: WHAT HAVE WE LEARNED IN 5 YEARS?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.6 ACUTE CORONARY SYNDROMES - CLINICAL

- PO 49 PREVALENCE OF HIGH LIPOPROTEIN (A) LEVELS IN PATIENTS WITH PREMATURE MYOCARDIAL INFARCTION: SYSTEMATIC REVIEW

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.7 ACUTE CORONARY SYNDROMES - OTHER**

- PO 50** LIPOPROTEIN(A) LEVELS IN ACUTE MYOCARDIAL INFARCTION PATIENTS AND THEIR ASSOCIATIONS WITH PRIOR EVENTS AND CORONARY ARTERY DISEASE SEVERITY: A REAL-WORLD COHORT STUDY

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.2 ACUTE CARDIAC CARE - PREHOSPITAL AND EMERGENCY DEPARTMENT CARE**

- PO 203** EVALUATING THE BENEFITS OF HIGH-DOSE STATIN LOADING IN STEMI MANAGEMENT: INSIGHTS FROM A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE**

- PO 211** THE HIDDEN THREAT OF SEPTIC CARDIOMYOPATHY: UNMASKING ITS IMPACT ON ICU SURVIVAL
- PO 212** DIAGNOSTIC PERFORMANCE OF BIOMARKERS IN PREDICTING SEPTIC CARDIOMYOPATHY: A STUDY ON PROCALCITONIN, NT-PROBNP, AND TROPONIN T IN SEPSIS PATIENTS
- PO 213** UNVEILING THE POPULATION DYNAMICS OF SEPSIS CARDIOMYOPATHY: A COMPREHENSIVE EVALUATION
- PO 214** MANAGEMENT OF NEW-ONSET ATRIAL FIBRILLATION IN THE INTENSIVE CARE UNIT: WHERE DO WE STAND?
- PO 215** ENDOMYOCARDIAL BIOPSY IN CARDIOGENIC SHOCK: EXPERIENCE FROM A CONTEMPORARY CICU PORTUGUESE COHORT
- PO 225** EFFICACY AND SAFETY OF IMPELLA VERSUS STANDARD OF CARE IN CARDIOGENIC SHOCK SECONDARY TO ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW
- PO 226** VASCULAR COMPLICATIONS IN INTRA-AORTIC BALLOON PUMP PATIENTS: INSIGHTS FROM A 20-YEAR SINGLE-CENTER EXPERIENCE
- PO 227** PREDICTORS OF MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION MANAGED WITH INTRA-AORTIC BALLOON ASSISTANCE: A 20-YEARS SINGLE-CENTER EXPERIENCE
- PO 250** EARLY DOAC THERAPY AFTER INVASIVE ACUTE PULMONARY EMBOLISM THERAPY: FAST TRACK PE?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK**

- CO 17** FULMINANT ACUTE MYOCARDITIS IN THE CARDIAC INTENSIVE CARE UNIT - A LONG BUT SUCCESSFUL ROAD TO RECOVERY
- CO 18** IMPACT OF DANGER SHOCK ELIGIBILITY CRITERIA ON SURVIVAL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION-RELATED CARDIOGENIC SHOCK: IT IS ALL ABOUT IMPELLA?
- PO 43** ACUTE KIDNEY INJURY, THE WORST NIGHTMARE IN PATIENTS WITH MYOCARDIAL INFARCTION AND CARDIOGENIC SHOCK
- PO 47** THE HEART-KIDNEY CONNECTION: ACUTE KIDNEY INJURY IN CARDIOGENIC SHOCK
- PO 229** PREDICTORS OF MORTALITY IN VA-ECMO PATIENTS: A RETROSPECTIVE COHORT ANALYSIS USING LASSO REGRESSION
- PO 230** SCAI CLASSIFICATION AS A PREDICTOR OF MORTALITY IN CARDIOGENIC SHOCK: WHAT IS THE BEST TIME TO CLASSIFY PATIENTS?
- PO 231** CLASSIC VERSUS NORMOTENSIVE CARDIOGENIC SHOCK: A SINGLE CENTER COMPARISON ANALYSIS
- PO 232** A SINGLE CENTER ANALYSIS EXPLORING MECHANICAL CIRCULATORY SUPPORT IN CARDIOGENIC SHOCK
- PO 233** PREDICTORS OF MORTALITY IN CARDIOGENIC SHOCK: CLINICAL STAGING AND CARDIOVASCULAR SUPPORT
- PO 243** EFFICACY AND SAFETY OF TICAGRELOR VERSUS CLOPIDOGREL IN ACUTE MYOCARDIAL INFARCTION-ASSOCIATED CARDIOGENIC SHOCK: A PROPENSITY SCORE-MATCHED ANALYSIS
- PO 244** ANTI-THROMBOTIC THERAPY FOR AMI-CS ON MECHANICAL CIRCULATORY SUPPORT: DO WE NEED DAPT?

- PO 245 PREDICTORS OF HEMORRHAGIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK UNDERGOING DUAL ANTIPLATELET THERAPY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 14. ACUTE CARDIAC CARE -> 14.6 ACUTE CARDIAC CARE - OTHER

- PO 208 TAKOTSUBO SYNDROME IN THE 21ST CENTURY: A PORTUGUESE PICTURE FROM A TERTIARY CENTER
PO 394 RISK ASSESSMENT IN PATIENTS WITH INTERMEDIATE TO HIGH-RISK PULMONARY EMBOLISM: CAN THE VALIDATED SCORES HELP PREDICT THE NECESSITY FOR REPERFUSION THERAPY?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

- PO 106 THE POTENTIAL ROLE OF ELEVATED LIPOPROTEIN(A) IN THE EARLY STAGES OF AORTIC VALVE STENOSIS
PO 193 SECONDARY MITRAL REGURGITATION SUBTYPES: LINKING ETIOLOGY, LEFT ATRIAL MECHANICS, AND CLINICAL PHENOTYPES
PO 253 GLOBAL LONGITUDINAL STRAIN AND STRAIN RATE AS MARKERS OF SUBCLINICAL SYSTOLIC DYSFUNCTION IN PATIENTS WITH MODERATE AORTIC STENOSIS
PO 268 IMPACT OF DIASTOLIC DYSFUNCTION IN PATIENTS WITH MODERATE AORTIC STENOSIS
PO 269 IS MYOCARDIAL ADAPTATION DISTINCT IN PATIENTS WITH BICUSPID VERSUS TRICUSPID SEVERE AORTIC STENOSIS UNDERGOING SURGICAL VALVE REPLACEMENT?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 152 CONDUCTION ABNORMALITIES POST-TAVI: IMPACT ON LVEF RECOVERY AND SURVIVAL
PO 194 DEVELOPMENT OF TRICUSPID REGURGITATION AFTER LEFT-SIDE HEART SURGERY
PO 259 RESERVOIR STRAIN OUTPERFORMS TRADITIONAL ECHOCARDIOGRAPHIC PARAMETERS IN PREDICTING MORTALITY IN SECONDARY MITRAL REGURGITATION
PO 335 ADVERSE EVENTS WHILE WAITING FOR VALVULAR INTERVENTION: IDENTIFYING MODIFIABLE RISK FACTORS
PO 373 MITRAL VALVE PROLAPSE: ARRHYTHMIC RISK AND PROGNOSIS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS

- PO 102 ASSESSING THE ROLE OF AORTIC VALVE CALCIUM SCORE IN PATIENTS WITH SEVERE AORTIC STENOSIS AND CHRONIC KIDNEY DISEASE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT

- CO 25 VENTRICULAR PACING RATE AND VENTRICULAR PACING DEPENDENCY IN PATIENTS REQUIRING PERMANENT PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
CO 38 EXPLORING IMPLANTATION DEPTH AND PROCEDURAL OUTCOMES IN TRANSCATHETER AORTIC VALVE REPLACEMENT
CO 92 PROGNOSTIC IMPACT OF MITRAL BALLOON VALVULOPLASTY FOR MITRAL STENOSIS PATIENTS: WHEN THE RIGHT HEART CATHETERIZATION IS THE ANSWER
CO 101 LESS-INVASIVE AORTIC VALVE REPLACEMENT: MID-TERM SINGLE-CENTER RESULTS

- PO 107 GENDER DIFFERENCE IMPACT ON TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSES
- PO 150 PREDICTORS OF ACUTE KIDNEY INJURY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 151 ATRIOVENTRICULAR VALVE REGURGITATION PROGRESSION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 154 EARLY AND LATE PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 155 PREDICTORS OF LEFT VENTRICULAR DYSFUNCTION RECOVERY ONE YEAR AFTER TAVR IN PATIENTS WITH PRE-EXISTING LEFT VENTRICULAR DYSFUNCTION (LVEF > 50%)
- PO 195 THE IMPACT OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR ON FUNCTIONAL OUTCOMES IN SECONDARY MITRAL REGURGITATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 196 IMPACT OF LEFT VENTRICULAR VOLUME AND EFFECTIVE REGURGITANT ORIFICE AREA ON MORTALITY EFFECTS OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-REGRESSION ANALYSIS
- PO 197 SAFETY AND EFFICACY OF TRANSCATHETER EDGE-TO-EDGE REPAIR IN ATRIAL FUNCTIONAL MITRAL REGURGITATION
- PO 337 A META-ANALYSIS ON 12-MONTH EFFICACY OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR VS SURGERY ON MITRAL REGURGITATION
- PO 339 PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: IS IT A CONSEQUENCE OF THE TYPE OF PROSTHESIS USED?
- PO 340 BALLOON VS SELF-EXPANDABLE VALVES - AV CONDUCTION DISTURBANCE
- PO 341 OVER- OR UNDER-SIZING OF VALVE PROSTHESES IN TAVR AND THE IMPORTANCE OF A BROADER RANGE OF SIZING OPTIONS TO ENSURE OPTIMAL VALVE FIT.

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

15. VALVULAR HEART DISEASE -> 15.6 VALVULAR HEART DISEASE - CLINICAL

- PO 153 KIDNEY FUNCTION FOLLOWING PERCUTANEOUS TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) IN HOSPITALIZED PATIENTS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

15. VALVULAR HEART DISEASE -> 15.7 VALVULAR HEART DISEASE - OTHER

- PO 104 THE MYOCARDIAL IMPACT OF RAPID PROGRESSION OF AORTIC STENOSIS
- PO 342 PROPRANOLOL FOR HEART RATE CONTROL IN PRE-TAVI CARDIAC CT: A PROSPECTIVE STUDY ON EFFICACY AND SAFETY IN SEVERE AORTIC STENOSIS PATIENTS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 80 IMPACT OF DELAYS IN DIAGNOSIS AND THERAPY ON MORTALITY IN PATIENTS WITH INFECTIVE ENDOCARDITIS
- PO 81 INFECTIVE ENDOCARDITIS AND ACUTE HEART FAILURE: A COHORT ANALYSIS OF RISK FACTORS AND MORTALITY
- PO 82 INFECTIVE ENDOCARDITIS - PREDICTORS OF CEREBRAL AND PERIPHERAL EMBOLIZATION AND MORTALITY
- PO 83 SPECIFIC PATHOGENS AND PROGNOSTIC OUTCOMES IN INFECTIVE ENDOCARDITIS: A RETROSPECTIVE ANALYSIS
- PO 84 AORTIC PROSTHETIC VALVE ENDOCARDITIS: CLINICAL CHARACTERISTICS, MICROBIOLOGICAL PROFILE AND OUTCOMES COMPARISON BETWEEN TRANSCATHETER AND SURGICAL BIOPROSTHESIS
- PO 101 IS PROCALCITONIN A GOOD PREDICTOR FOR IN-HOSPITAL MORTALITY IN INFECTIVE ENDOCARDITIS?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

16. INFECTIVE ENDOCARDITIS -> 16.3 INFECTIVE ENDOCARDITIS - DIAGNOSTIC METHODS

- PO 96 CLINICAL RULE FOR INFECTIVE ENDOCARDITIS IN THE EMERGENCY DEPARTMENT SCORE: A PREDICTION TOOL FOR INFECTIVE ENDOCARDITIS AND ITS EMBOLIC EVENTS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

16. INFECTIVE ENDOCARDITIS -> 16.4 INFECTIVE ENDOCARDITIS - TREATMENT

- PO 97** ANTIBIOTIC THERAPY FOR ENDOCARDITIS IN OUTPATIENT SETTING: IS IT INEFFECTIVE AND SAFE IN LOW RISK PATIENTS?
- PO 98** THE BURDEN OF INFECTIVE ENDOCARDITIS IN A CENTER WITHOUT CARDIAC SURGERY: A RETROSPECTIVE ANALYSIS
- PO 99** COMPREHENSIVE MANAGEMENT OF INFECTIVE ENDOCARDITIS: CLINICAL FINDINGS AND SURGICAL OUTCOMES
- PO 100** VANCOMYCIN THERAPY AND ACUTE KIDNEY INJURY IN PATIENTS WITH INFECTIVE ENDOCARDITIS
- PO 336** PROSTHETIC VALVE ROCKING MOTION: A LOOK OVER THE LAST TEN YEARS IN A TERTIARY CARE CENTER
- PO 338** URGENT SURGERY FOR INFECTIVE ENDOCARDITIS: ARE WE FALLING BEHIND THE CLOCK?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- CO 27** ECHOCARDIOGRAPHIC PREDICTORS OF DEATH IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- CO 28** PREDICTORS OF ATRIAL FIBRILLATION IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- CO 100** RADIOMICS-BASED ARTIFICIAL INTELLIGENCE MODEL ALLOWS FOR PERSONALIZED PREDICTION OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 34** A COMPREHENSIVE CHARACTERIZATION OF FAMILIAL AMYLOID POLYNEUROPATHY PATIENTS WITH PACEMAKER IMPLANTATION
- PO 35** CLINICAL OUTCOMES IN FAMILIAL AMYLOID POLYNEUROPATHY PATIENTS: THE EFFECT OF PACEMAKER IMPLANTATION
- PO 41** RIGHT VENTRICULAR FUNCTION ANALYSIS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: IDENTIFYING THE BEST PREDICTOR OF PATIENT OUTCOMES
- PO 42** PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: INSIGHTS FROM A REGIONAL HOSPITAL EXPERIENCE
- PO 114** FROM GENES TO OUTCOMES: THE PROGNOSTIC ROLE OF GENETIC MUTATIONS IN DILATED CARDIOMYOPATHY
- PO 179** SYSTOLIC FUNCTION PREDICTORS IN PATIENTS WITH TAKOTSUBO SYNDROME
- PO 260** LEFT ATRIAL STRAIN AS A PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 298** SUDDEN CARDIAC DEATH HCM RISK SCORES IN APICAL HYPERTROPHIC CARDIOMYOPATHY: AN UNMET NEED IN CLINICAL PRACTICE
- PO 302** IS NON-SUSTAINED VENTRICULAR TACHYCARDIA A KEY PLAYER IN NON-ISCHEMIC CARDIOMYOPATHY?
- PO 383** IMPLICATIONS OF MYOCARDIAL BRIDGING ON HEART RHYTHM IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 384** INTEGRATING GENETIC VARIANTS INTO HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION: A QUANTITATIVE AND COMPARATIVE ANALYSIS
- PO 385** ALPHA-TROPOMYOSIN GENE VARIANTS IN HYPERTROPHIC CARDIOMYOPATHY: CLINICAL FEATURES AND DISEASE PROGRESSION
- PO 386** LEFT VENTRICULAR EJECTION FRACTION AS A PREDICTOR OF MAJOR VENTRICULAR ARRHYTHMIC EVENTS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS WITH AN ICD IN PRIMARY PREVENTION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS

- PO 36** MULTIPARAMETRIC ECHOCARDIOGRAPHY SCORES FOR TRANSTHYRETIN CARDIAC AMYLOIDOSIS DIAGNOSIS - IS THE INCREASED WALL THICKNESS SCORE APPROPRIATE?
- PO 37** TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) CARDIOGENOMICS: A TERTIARY CENTRE EXPERIENCE
- PO 118** GENETIC MUTATIONS AND TESTING PROFILES LANDSCAPE IN DILATED CARDIOMYOPATHY PATIENTS: A DIAGNOSTIC IMPACT ANALYSIS
- PO 119** REFINING GENETIC PREDICTION IN DILATED CARDIOMYOPATHY: EVALUATING THE MADRID SCORE AND ENHANCED MACHINE LEARNING MODELS WITH CLINICAL AND IMAGING DATA
- PO 387** SCREENING FOR ANDERSON-FABRY DISEASE IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY AND DISEASE-RELATED "RED FLAGS"

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT**

- CO 29 DECODING THE DECADES: TAFAMIDIS EFFICACY ACROSS DIFFERENT AGE GROUPS IN ATTR-CM PATIENTS
- CO 76 MAVACAMTEN USE IN A REAL-WORLD COHORT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS: INSIGHTS FROM THE INITIAL CENTRE EXPERIENCE
- CO 77 EFFECT OF MAVACAMTEN ON THE REMODELLING AND MICROSTRUCTURAL ARCHITECTURE OF THE MYOCARDIUM: A PRELIMINARY MECHANISTIC STUDY
- CO 78 ECHOCARDIOGRAPHIC EVOLUTION OF SYMPTOMATIC PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TREATED WITH MAVACAMTEN: EXPERIENCE OF A PORTUGUESE TERTIARY CARE CENTER
- PO 38 ATTR-CM UNDER THE MICROSCOPE: COMPARING REAL-WORLD WITH TRIAL OUTCOMES
- PO 39 NAVIGATING TAFAMIDIS OUTCOMES ACROSS DIFFERENT DISEASE SEVERITIES IN ATTR-CM
- PO 40 NON-CONVENTIONAL VERSUS CONVENTIONAL PACING IN CARDIAC AMYLOIDOSIS: IMPACT ON CLINICAL, ELECTRICAL, AND FUNCTIONAL OUTCOMES
- PO 115 GENDER DIFFERENCES IN MYOCARDIAL REVERSE REMODELING AFTER GUIDELINE-DIRECTED MEDICAL THERAPY IN DILATED CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.5 MYOCARDIAL DISEASE - PREVENTION**

- PO 116 PREDICTING ATRIAL FIBRILLATION - CAN ATRIAL PARAMETERS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE BE THE KEY IN DILATED CARDIOMYOPATHY?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL**

- CO 30 AMYLOID CARDIOMYOPATHY: SPECIFICITIES OF TRANSTHYRETIN V30 MUTATION COMPARED TO WILD TYPE FORMS
- PO 117 FORECASTING VENTRICULAR ARRHYTHMIAS IN DILATED CARDIOMYOPATHY: A FOCUS ON CARDIAC IMPLANTABLE ELECTRONIC DEVICES PATIENTS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.7 MYOCARDIAL DISEASE - OTHER**

- PO 374 DO IMPLANTABLE LOOP RECORDERS HAVE A ROLE IN HYPERTROPHIC CARDIOMYOPATHY?
- PO 388 ATRIAL FIBRILLATION PREDICTORS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 85 THE FAILING FONTAN: FROM THE SUCCESSFUL PALLIATION TO THE UNAVOIDABLE NOT-SO-SLOWLY PROGRESSIVE FAILURE OF THE CIRCUIT

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.6 CONGENITAL HEART DISEASE - CLINICAL**

- PO 86 ADULTS WITH FONTAN CIRCULATION: INSIGHTS FROM A PORTUGUESE ADULT CONGENITAL HEART DISEASE CENTER

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.1
PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - PATHOPHYSIOLOGY
AND MECHANISMS**

- CO 6** PULMONARY ARTERY PULSE PRESSURE AS A PREDICTOR OF PULMONARY HYPERTENSION IN PATIENTS
WITH INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY,
PROGNOSIS, OUTCOME**

- CO 7** IMPROVING RISK PREDICTION IN PULMONARY HYPERTENSION: THE ROLE OF PULMONARY ARTERIAL COMPLIANCE
PO 87 SIX-MINUTE WALKING TEST AND CARDIOPULMONARY EXERCISE TEST IN PULMONARY HYPERTENSION RISK ASSESSMENT
PO 88 OXYGEN THERAPY IN CTEPH PATIENTS: PREVALENCE AND ASSOCIATED FACTORS
PO 89 PROGNOSTIC VALUE OF THE COMPOSITE PULMONARY EMBOLISM SHOCK SCORE IN ACUTE INTERMEDIATE-RISK
PULMONARY EMBOLISM
PO 90 INCIDENCE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER SEVERE FORMS OF ACUTE PULMONARY
EMBOLISM: SYSTEMATIC REVIEW WITH META-ANALYSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC
METHODS**

- CO 8** PERSUING VENTRICULAR-ARTERIAL COUPLING: PROPOSING A NEW CUT-OFF OF TAPSE/SPAP TO IDENTIFY PATIENTS
WITH PULMONARY HYPERTENSION AFTER INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM
CO 84 REALLY WORTH THE EFFORT: UNVEILING EXERCISE PULMONARY HYPERTENSION - A SINGLE CENTRE EXPERIENCE
PO 91 RIGHT ATRIAL PRESSURE ESTIMATION BY ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION - TIME FOR A
CHANGE?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -
TREATMENT**

- CO 9** PULMONARY ENDARTERECTOMY AND BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC
PULMONARY HYPERTENSION: COMPARISON OF LONG-TERM HEMODYNAMIC RESPONSES TO EXERCISE
PO 92 BREAKING NEW GROUND IN PULMONARY ENDARTERECTOMY: INITIAL EXPERIENCE OF A PORTUGUESE SINGLE
CENTER
PO 93 LONG-TERM SURVIVAL WITH PARENTERAL PROSTACYCLIN THERAPY IN PULMONARY HYPERTENSION - INSIGHTS
FROM A REFERRAL CENTER IN PORTUGAL

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.6 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - CLINICAL**

- CO 10** TAPSE/PASP RATIO: UNVEILING A KEY PREDICTOR OF PULMONARY HYPERTENSION IN ACUTE PULMONARY
EMBOLISM
PO 94 QTC INTERVAL INDEPENDANTLY PREDICTS OUTCOMES IN ACUTE PULMONARY EMBOLISM

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 2

1. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.7

PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - OTHER

PO 95 PULMONARY EMBOLISM IN ANTICOAGULATED PATIENTS: A RETROSPECTIVE SINGLE-CENTERED COHORT COMPARING DATA FROM THE PIOPED II STUDY

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->

22.3 AORTIC DISEASE - DIAGNOSTIC METHODS

CO 93 THE IMPACT OF AORTIC DISTENSIBILITY IN PATIENTS WITH BICUSPID AORTIC VALVE STENOSIS

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE -> 2

2.4 AORTIC DISEASE - TREATMENT

PO 333 EARLY AND LONG-TERM OUTCOMES AFTER AORTIC VALVE REPAIR: A SYSTEMATIC REVIEW AND META-ANALYSIS USING RECONSTRUCTED INDIVIDUAL PATIENT DATA

PO 343 POST-TAVI PACEMAKER REQUIREMENT PREDICTION - SIMPLE MATH?

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->

22.6 AORTIC DISEASE - CLINICAL

PO 334 CLINICAL AND IMAGING SURVEILLANCE OF SURVIVORS OF ACUTE TYPE A AORTIC DISSECTION

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.7 HEART AND BRAIN INTERACTION

PO 344 PREDICTORS OF EARLY STROKE AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT

CO 41 UNFREEZING THE PATH WITH ICE-ING: REVOLUTIONIZING LEFT ATRIAL APPENDAGE OCCLUSION

CO 64 STRUCTURAL INVASIVELY-ASSESSED CORONARY MICROVASCULAR DYSFUNCTION PHENOTYPE ASSOCIATES WITH THE PRESENCE OF MYOCARDIAL FIBROSIS IN CARDIAC MAGNETIC RESONANCE

CO 102 DEVELOPMENT AND VALIDATION OF AN OPEN-SOURCE 3D SLICER PLUGIN FOR TAVI SIZING

PO 25 OUTCOMES WITH PLUG-BASED VERSUS SUTURE-BASED VASCULAR CLOSURE DEVICE AFTER TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

PO 271 SAFETY AND OUTCOMES OF IFR VS. FFR IN CORONARY REVASCULARIZATION: A REAL-WORLD COHORT STUDY

PO 272 CORONARY PHYSIOLOGY IN IN PATIENTS WITH ANGINA AND NON-OBSTRUCTIVE CORONARY ARTERY DISEASE - PRELIMINARY DATA FROM MULTICENTER REGISTRY.

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.2 CORONARY INTERVENTION

CO 45 TO STENT OR NOT TO STENT IN TRUE BIFURCATION: WHAT IS THE BEST APPROACH FOR THE SIDE BRANCH IN A LEFT MAIN ARTERY BIFURCATION?

PO 44 CONTRAST VOLUME TO CREATININE CLEARANCE RATIO - A STRONG PREDICTOR OF CONTRAST INDUCED NEPHROPATHY IN PATIENTS UNDERGOING PERCUTANEOUS INTERVENTION

PO 205 TEMPORAL TREND OF DRUG ELUTING BALLOON OVER THE LAST 10 YEARS

- PO 206 EXPERIENCE WITH DRUG-ELUTED BALLOONS: INSIGHTS FROM A TERTIARY CARE CENTRE
- PO 270 NAVIGATING THE CORONARY CROSSROADS: LEFT MAIN ARTERY BIFURCATING LESIONS, A SINGLE CENTRE PCI RESULTS
- PO 274 ONE-YEAR OUTCOMES OF ALCOHOLIC SEPTAL ABLATION IN A TERTIARY REFERENCE CENTER
- PO 278 PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN CORONARY ARTERY: ACUTE AND CHRONIC DISEASE

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

- CO 36 FINDING THE PERFECT MATCH: PROFILING AORTIC ANNULUS IN TAVI PATIENTS
- CO 37 TRANSCATHETER AORTIC VALVE IMPLANTATION WITHOUT CARDIAC SURGERY BACKUP: FIRST NATIONAL SINGLE-CENTER EXPERIENCE ASSESSING SAFETY AND EFFICACY OUTCOMES
- CO 39 TAVI PARAVALVULAR LEAKS - 1 YEAR EVALUATION AND MULTIMODAL PREDICTORS
- CO 42 IMPROVING PATIENT SELECTION FOR PERCUTANEOUS SUTURE-MEDIATED PATENT FORAMEN OVALE CLOSURE: THE SWAT CRITERIA
- CO 43 PERCUTANEOUS SUTURE-MEDIATED PATENT FORAMEN OVALE CLOSURE: RESULTS FROM THE LARGEST NATIONAL REGISTRY
- CO 44 TRANSCATHETER PULMONARY VALVE IMPLANTATION EXPERIENCE IN A PORTUGUESE CONGENITAL HEART DISEASE CENTER
- CO 75 ACUTE KIDNEY INJURY POST-TAVI: DOES IT STILL IMPACT PROGNOSIS?
- PO 26 VASCULAR COMPLICATIONS AFTER MANTA VASCULAR CLOSURE DEVICE FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 27 EARLY DISCHARGE SAFETY IN TAVI PATIENTS WITH NEW-ONSET LEFT BUNDLE BRANCH BLOCK
- PO 28 OPTIMIZING TAVI - SHOULD PREEMPTIVE PACING BE CONSIDERED IN ADVANCED CONDUCTION DISEASE?
- PO 29 INITIAL EXPERIENCE WITH EVOLUT FX: HOW DOES IT MEASURE UP?
- PO 30 PROGNOSTIC VALUE OF QRS VARIATION FOLLOWING TAVI: A PREDICTOR OF LEFT VENTRICULAR DYSFUNCTION AND MORTALITY AT 1-YEAR FOLLOW UP
- PO 31 CLINICAL PROFILING ON CLUSTERING TAVI PATIENTS: MULTIVARIATE ANALYSIS OF RISK FACTORS, CLINICAL PRESENTATION, AND OUTCOME ASSOCIATION
- PO 216 TAVI OUTCOME ANALYSIS IN OFF-LABEL ANATOMIC SETTINGS
- PO 217 TAVI IN PURE AORTIC INSUFFICIENCY: OUR CASE SERIES
- PO 218 TRANSCATHETER AORTIC VALVE REPLACEMENT IN DIALYSIS PATIENTS: SURVIVAL AND COMPLICATION RATES - A SINGLE CENTER EXPERIENCE
- PO 219 OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN YOUNG LOW-RISK PATIENTS: A COMPREHENSIVE META-ANALYSIS OF EFFICACY AND SAFETY.
- PO 220 ADDRESSING SMALL ANNULUS IN TAVR: PROCEDURAL SUCCESS AND CLINICAL OUTCOMES
- PO 222 CLASSIC CLARITY, PARADOXICAL PUZZLE: PROGNOSTIC EVALUATION IN LOW FLOW LOW GRADIENT AORTIC STENOSIS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 223 LEFT VENTRICULAR EJECTION FRACTION IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT - PREDICTORS AND PROGNOSIS
- PO 224 INTRA-HOSPITAL OUTCOMES FOR TAVR UNDER 75: CAN IT HOLD A CANDLE TO SAVR?
- PO 360 COMPARISON OF REAL-WORLD MITRAL TEER OUTCOMES WITH COAPT AND MITRA-FR: A SINGLE-CENTER ANALYSIS
- PO 367 IMPACT OF ETIOLOGY, AGE AND LEFT VENTRICULAR EJECTION FRACTION ON 12-MONTH MORTALITY EFFECTS OF TRANSCATHETER EDGE-TO-EDGE REPAIR VS. SURGERY: A META-REGRESSION ANALYSIS
- PO 368 COMPARING 30-DAY OUTCOMES OF TRANSCATHETER EDGE-TO-EDGE REPAIR VS SURGERY IN MITRAL VALVE REGURGITATION: A META-ANALYSIS OF CLINICAL TRIALS AND PROPENSITY-MATCHED COHORTS
- PO 390 SEX DIFFERENCES IN PATENT FORAMEN OVALE CLOSURE: IMPACT ON OUTCOMES AND COMPLICATIONS
- PO 391 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN ANTICOAGULATION FAILURE VS CONTRAINDICATION
- PO 392 COMPARATIVE OUTCOMES OF IN SITU FIBRINOLYSIS VERSUS MECHANICAL AND COMBINED TECHNIQUES IN REDUCING RIGHT HEART PRESSURES AND MORTALITY IN PULMONARY EMBOLISM PATIENTS

PO 393 IMPACT OF MECHANICAL THROMBECTOMY USING THE FLOWTRIEVER SYSTEM ON HEMODYNAMICS AND SAFETY IN ACUTE PULMONARY EMBOLISM

PO 395 ENCERRAMENTO DE FOP POR SÍNDROME DE PLATIPNEIA-ORTODEOXIA NUM CENTRO NACIONAL

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER

CO 40 IS SMART ENOUGH? BEV VS SEV IN PATIENTS WITH SMALL AORTIC ANNULI

PO 32 A COMPARISON OF SELF-EXPANDING AND BALLOON-EXPANDABLE VALVES IN PACEMAKER IMPLANTATION RATES IN TAVI

PO 33 COMPARATIVE ANALYSIS OF DEVICE PERFORMANCE AND PACEMAKER IMPLANTATION RATES IN SUPRA-ANULAR AND INTRA-ANULAR TAVR VALVES IN PATIENTS WITH SMALL AORTIC ANNULI

PO 273 IMPLICATIONS OF USING A RADIATION PROTECTION CABIN IN THE CARDIAC CATHETERIZATION LABORATORY

PO 361 TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION: A META-ANALYSIS OF MORTALITY OUTCOMES

PO 389 LEFT ATRIAL APPENDAGE OCCLUSION IN COMBINATION WITH ANOTHER CARDIAC PROCEDURE: A MORE EFFICIENT APPROACH?

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.1 CARDIOVASCULAR SURGERY - CORONARY ARTERIES

PO 365 INFLUENCE OF GENDER ON LIFE EXPECTANCY AFTER CORONARY ARTERY BYPASS SURGERY

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.2 CARDIOVASCULAR SURGERY - VALVES

PO 23 AORTIC VALVE REPLACEMENT IN OCTOGENARIANS: IMPACT ON AGE-EXPECTED SURVIVAL

PO 221 CHALLENGES AND OUTCOMES OF AORTIC VALVE INTERVENTION: INSIGHTS FROM A SINGLE-CENTER STUDY ON SEVERE HIGH-GRADIENT AORTIC STENOSIS

PO 362 ISOLATED TRICUSPID VALVE SURGERY PATIENT PROFILE, RISK SCORE AND OUTCOME ASSOCIATION: SINGLE CENTER EXPERIENCE

PO 363 PREDICTORS AND OUTCOMES OF PROSTHESIS-PATIENT MISMATCH AFTER TRIFECTA BIOPROSTHETIC AORTIC VALVE REPLACEMENT

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER

PO 366 ADDRESSING COMPLICATIONS IN INFECTIVE ENDOCARDITIS: THE CRITICAL ROLE OF SURGICAL INTERVENTION POST-2023 GUIDELINES

I. HYPERTENSION -> 27. HYPERTENSION -> 27.5 HYPERTENSION - PREVENTION

PO 163 CAN THE GENE VARIANT ZC3HC1 RS11556924 C>T INCREASE ESSENTIAL HYPERTENSION RISK? INFLUENCE OF SMOKING IN THE RELATIONSHIP.

I. HYPERTENSION -> 27. HYPERTENSION -> 27.6 HYPERTENSION - CLINICAL

PO 64 COMPARISON BETWEEN OFFICE BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE MONITORING IN PREDICTING CARDIOVASCULAR EVENTS

I. HYPERTENSION -> 27. HYPERTENSION -> 27.7 HYPERTENSION - OTHER

CO 4 FIBRINOGEN IS CORRELATED TO INCREASED ARTERIAL STIFFNESS ON HYPERTENSIVE INDIVIDUALS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY

- CO 85** TEACHING YOUR HEART TO HEAL: THE ROLE OF PATIENT EDUCATION IN IMPROVING OUTCOMES IN PRIMARY ANGIOPLASTY FOR STEMI
- PO 63** DIFFERENCES IN OVERWEIGHT AND OBESITY PREVALENCE AMONG PRIMARY SCHOOL CHILDREN IN SÃO JOÃO DA MADEIRA, PORTUGAL
- PO 65** EXPLORING CORRELATION BETWEEN ADIPOSITY AND BLOOD PRESSURE AND THE IMPACT OF EXERCISE IN PRIMARY SCHOOL CHILDREN FROM SÃO JOÃO DA MADEIRA.

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT

- CO 33** ASSOCIATIONS BETWEEN AN INSULIN RESISTANCE INDEX AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION IN A CORONARY POPULATION
- CO 34** C-REACTIVE PROTEIN LEVEL AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE
- CO 65** EPICARDIAL ADIPOSE TISSUE VOLUME ARE RELATED TO SUBCLINICAL ATHEROSCLEROSIS AND MAJOR ADVERSE CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS
- CO 83** NONSPECIFIC VENTRICULAR REPOLARIZATION ABNORMALITIES: A BENIGN FINDING OR A PROGNOSTIC CONCERN?
- PO 66** IMPACT OF SUBCLINICAL PRIMARY ALDOSTERONISM ON VALVULAR, CORONARY AND AORTIC CALCIFICATION: A POPULATION-BASED COHORT STUDY
- PO 166** THE ADDITION OF A POLYGENIC RISK SCORE TO A CLINICAL RISK SCORE IN THE PREDICTION OF CARDIOVASCULAR DISEASE
- PO 182** ANTICOAGULATION AFTER CAVOTRICUSPID ISTHMUS-DEPENDENT ATRIAL FLUTTER ABLATION: ESSENTIAL OR OVERUSED?
- PO 235** THE IMPORTANCE OF FIBRINOGEN AS A CARDIOVASCULAR RISK FACTOR
- PO 311** LONG-TERM CARDIOVASCULAR RISK ASSESSMENT IN PORTUGUESE CHRONIC KIDNEY DISEASE POPULATION: INSIGHTS FROM THE PREVENTTM SCORE
- PO 313** BASELINE CARDIOVASCULAR RISK AND PRIMARY PREVENTION IN STEMI PATIENTS: INSIGHTS FROM A TERTIARY CENTER

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION

- CO 35** IDENTIFYING REDUCE-IT TRIAL ELIGIBLE PATIENTS IN A STRUCTURED CORONARY DISEASE FOLLOW-UP PROGRAM
- PO 173** LOW DOSE COLCHICINE FOR SECONDARY PREVENTION IN PATIENTS WITH PREVIOUS ATHEROSCLEROTIC EVENT: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.4 LIPIDS

- CO 2** THE ROLE OF AGE ON LIPID-LOWERING THERAPY PRESCRIPTIONS AND ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) CONTROL: A SUBANALYSIS OF THE PORTRAIT-DYS STUDY
- CO 31** IMPACT OF LIPOPROTEIN A ON LONG-TERM OUTCOMES IN ACUTE CORONARY SYNDROME: A RETROSPECTIVE COHORT ANALYSIS
- PO 236** THE ROLE OF THE TRIGLYCERIDE-GLUCOSE INDEX AS A PREDICTOR OF CORONARY ARTERY DISEASE SEVERITY IN YOUNG PATIENTS
- PO 238** LIPOPROTEIN(A) AND ACUTE CORONARY SYNDROME: ASSOCIATIONS WITH SEX, AGE AND TRADITIONAL CARDIOVASCULAR RISK FACTORS
- PO 240** LDL ON TARGET - STRIKE EARLY AND STRIKE STRONG... JUST STRIKE!
- PO 242** LONG-TERM LIPID TARGET ACHIEVEMENT AFTER ACUTE MYOCARDIAL INFARCTION AND ISCHEMIC STROKE: A REAL-WORLD ANALYSIS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.5 TOBACCO

- CO 3** THE ROLE OF THE PHACTR1 GENE IN CORONARY ARTERIAL DISEASE IN SMOKERS WITH FEW OTHER CARDIOVASCULAR RISK FACTORS.

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.6 OBESITY

- PO 162** ASSOCIATION OF SLC30A8 RS1326634 GENE VARIANT WITH CENTRAL FAT DISTRIBUTION IN OVERWEIGHT AND OBESE WOMEN
- PO 165** HOW GENETIC VARIANTS AND EXCESS OF WEIGHT INFLUENCE RISK OF CORONARY ARTERY DISEASE

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.12 PHYSICAL INACTIVITY AND EXERCISE

- PO 164** GENETIC CONTRIBUTION TO CAD IN PATIENTS WITH FEW TRADITIONAL RISK FACTORS BUT A SEDENTARY LIFESTYLE

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER

- CO 32** CORONARY ARTERY DISEASE AND THE BAD DUAL: HOMOCYSTEINE AND LIPOPROTEIN (A)
- PO 160** RESTING ENERGY EXPENDITURE AS A SURROGATE OF MUSCLE MASS QUANTIFICATION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: A PILOT PROSPECTIVE COHORT STUDY
- PO 241** ASSOCIATION BETWEEN LIPOPROTEIN(A) AND RENAL FUNCTION: INSIGHTS FROM A CROSS-SECTIONAL STUDY

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING

- PO 17** ROLE OF PHASE 3 CARDIAC REHABILITATION IN IMPROVING CARDIORESPIRATORY FITNESS
- PO 161** THE ROLE OF CPET FOR THE ASSESSMENT OF PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION

- CO 81** MYERS AND MECKI SCORES IN CARDIAC REHABILITATION - COMPREHENSIVE AND SIMPLE AND RELIABLE TOOLS FOR RISK STRATIFICATION.
- CO 82** THE ROLE OF PEAK VO₂ IN CARDIAC REHABILITATION: PREDICTORS OF NON-RESPONSE AND THEIR IMPACT ON LONG-TERM OUTCOMES
- PO 1** THE ROLE OF PHASE 3 CARDIAC REHABILITATION IN BOOSTING PEAK VO₂ AND PREDICTING CLINICAL SUCCESS
- PO 2** IMPROVEMENT IN CARDIOPULMONARY EXERCISE TEST PARAMETERS PHASE 2 REHABILITATION AND ITS IMPACT ON CLINICAL OUTCOMES
- PO 3** THE CLINICAL AND HOLISTIC IMPACT OF A PROGRAM OF CARDIAC REHABILITATION
- PO 4** IMPACT OF COMPLETING CARDIAC REHABILITATION PROGRAM ON CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME
- PO 5** UNLOCKING PHYSICAL POTENTIAL: THE CRUCIAL ROLE OF CARDIAC REHABILITATION IN ENHANCING PHYSICAL CAPACITY
- PO 7** SECONDARY PREVENTION AFTER ONE-YEAR OF A CARDIOVASCULAR REHABILITATION PROGRAM - A SINGLE-CENTRE ANALYSIS
- PO 8** CLINICAL CHALLENGES IN CARDIOVASCULAR REHABILITATION PROGRAMS: PREDICTORS OF DROPOUT - A SINGLE-CENTRE ANALYSIS
- PO 9** AGE-RELATED DIFFERENCES IN CARDIOVASCULAR REHABILITATION PROGRAMS - A SINGLE-CENTRE ANALYSIS

- PO 10 EXPLORING PEAK CIRCULATORY POWER AND ITS CORRELATION WITH EXERCISE TEST PARAMETERS IN CARDIAC REHABILITATION
- PO 11 LONG-TERM IMPACT OF EXERCISE-BASED CARDIAC REHABILITATION ON CARDIORESPIRATORY FITNESS AND PHYSICAL FUNCTION
- PO 12 IMPACT OF STRUCTURED CARDIAC REHABILITATION ON PATIENT OUTCOMES: A PROSPECTIVE COHORT ANALYSIS
- PO 13 BODY MASS INDEX AS A PREDICTOR OF CLINICAL AND FUNCTIONAL OUTCOMES IN CARDIAC REHABILITATION
- PO 14 INFLUENCE OF CARDIAC REHABILITATION ADHERENCE ON CARDIOVASCULAR OUTCOMES
- PO 15 PHASE 2 CARDIOVASCULAR REHABILITATION: A STUDY ON POPULATION PROFILES AND OUTCOMES
- PO 16 ADHERENCE TO PHASE 3 CARDIAC REHABILITATION: PREDICTORS AND OUTCOMES
- PO 18 CARDIAC REHABILITATION PHASE 3 - WHO ARE THEY?
- PO 62 CARDIAC REHABILITATION IN OBESE PATIENTS: A POPULATION AT INCREASED RISK
- PO 156 BRIDGING THE GENDER GAP IN CARDIAC REHABILITATION: LONGITUDINAL PATTERNS OF PHYSICAL ACTIVITY ENGAGEMENT
- PO 158 CARDIAC REHABILITATION: IMPROVING FITNESS AND PERFORMANCE METRICS IN CORONARY ARTERY DISEASE
- PO 159 HIGH-INTENSITY INTERVAL AND CONTINUOUS TRAINING FOR HEART TRANSPLANT PATIENTS AND ITS IMPACT ON HEART RATE RECOVERY

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.3 SPORTS CARDIOLOGY

- PO 6 AWARENESS OF COMPETITIVE ATHLETES REGARDING CARDIOVASCULAR PROFILE, SPORTS MEDICINE EVALUATION AND EMERGENCY SUPPORT - SUPORT STUDY

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.1 CARDIOVASCULAR DISEASE IN PRIMARY CARE

- PO 234 FIBRINOGEN IS A PREDICTOR OF CEREBROVASCULAR DISEASE RISK IN A PORTUGUESE POPULATION

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.2 CARDIOVASCULAR DISEASE IN WOMEN

- CO 54 THE RELATIONSHIP BETWEEN SEX AND CARDIAC RESYNCHRONIZATION THERAPY: WHAT ABOUT WOMEN?
- PO 109 MYOCARDIAL INFARCTION AND GENDER DIFFERENCES IN ELDERLY PATIENTS
- PO 110 BRIDGING THE GENDER GAP IN TAVI: REAL-WORLD EVIDENCE FROM A SINGLE-CENTER STUDY
- PO 111 SEX-DIFFERENCES AND LONG-TERM OUTCOMES AFTER AORTIC VALVE REPLACEMENT
- PO 112 UNDERINFORMED AND OVERLOOKED: THE STATE OF CARDIOVASCULAR HEALTH LITERACY IN PORTUGUESE WOMEN
- PO 113 ACUTE CORONARY SYNDROME IN YOUNG WOMEN: RISK FACTORS AND LONG-TERM PROGNOSIS

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.3 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS: PEDIATRIC CARDIOLOGY

- PO 21 TEVAR PLUS BALLOON EXPANDABLE STENT: A NOVEL HYBRID ENDOVASCULAR APPROACH FOR COMPLEX COARCTATION OF AORTA REPAIR.

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.5 CARDIOVASCULAR DISEASE IN THE ELDERLY

- CO 95 AGING HEARTS: TRANSCATHETER AORTIC VALVE REPLACEMENT ASSESSMENT IN THE NONAGENARIAN POPULATION - A SINGLE CENTER EXPERIENCE

- PO 22 CHARACTERISATION OF PRE-INTERVENTION OUTCOMES IN VERY OLD PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 70 EVALUATING THE PREDICTIVE VALUE OF FRAILTY SCORES ON MORTALITY IN PATIENTS WITH CARADIOGENIC SHOCK ACROSS THE AGE SPECTRUM.

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY

- CO 47 CLOSING THE GAP: LEFT ATRIAL APPENDAGE OCCLUSION IN ATRIAL FIBRILLATION PATIENTS WITH CANCER
- CO 48 BODY FAT AS A PREDICTOR OF IMPAIRED CARDIORESPIRATORY FITNESS IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES
- CO 69 MYOCARDIAL WORK AND EXERCISE LVEF AS PREDICTORS OF IMPAIRED CARDIORESPIRATORY FITNESS IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES
- PO 73 MANAGING CARDIOVASCULAR RISK IN CANCER PATIENTS: THE IMPACT OF CANCER THERAPIES ON NEW-ONSET HEART FAILURE
- PO 75 THE DELICATE BALANCE OF PERMISSIVE CARDIOTOXICITY STRATEGY IN CANCER-RELATED CARDIAC DYSFUNCTION AT A TERTIARY CENTRE: A COMPARATIVE ANALYSIS
- PO 76 CANCER THERAPY SUSPENSION DUE TO CARDIOVASCULAR TOXICITY: RISK FACTORS AND OUTCOMES
- PO 78 CARDIOTOXICITY IN IBRUTINIB-TREATED PATIENTS: INCIDENCE, MANAGEMENT, AND IMPACT ON TREATMENT OUTCOMES
- PO 147 THE HIDDEN COST OF ANTHRACYCLINES: CARDIAC DYSFUNCTION AND FUNCTIONAL IMPAIRMENT IN BREAST CANCER
- PO 184 UNMASKING THE HEART'S RESPONSE: ATRIAL FIBRILLATION IN IBRUTINIB-TREATED PATIENTS
- PO 185 IMPACT OF CANCER THERAPIES ON ATRIAL FIBRILLATION: INCIDENCE, RISK FACTORS, AND CLINICAL IMPLICATIONS
- PO 378 18F-FDG UPTAKE: A POTENTIAL BIOMARKER FOR THORACIC AORTIC INFLAMMATION IN HYPERTENSIVE BREAST CANCER PATIENTS
- PO 379 CARDIOVASCULAR TOXICITY PREDICTION IN BREAST CANCER PATIENTS: THE HFA/ICOS RISK TOOL IN REAL-WORLD PRACTICE
- PO 380 CARDIOVASCULAR TOXICITY RISK STRATIFICATION IN CANCER PATIENTS: AN UNMET NEED IN CARDIO-ONCOLOGY
- PO 381 CHEMOTHERAPY-INDUCED CARDIOVASCULAR RISK FACTORS IN BREAST CANCER PATIENTS: WHAT'S NEW?
- PO 382 CARDIOTOXICITY ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: MYTH OR REALITY?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE

- CO 90 CHARACTERISATION OF LEFT ATRIAL DEFORMATION DURING CARDIOVASCULAR REVERSE REMODELLING INDUCED BY PREGNANCY AND ITS POTENTIAL PREDICTORS
- PO 314 IMPACT OF MATERNAL-FETAL OUTCOMES AND BREASTFEEDING ON CARDIAC REVERSE REMODELING

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.9 RENAL FAILURE AND CARDIOVASCULAR DISEASE

- PO 180 LEFT ATRIAL APPENDAGE OCCLUSION IN CKD: A SAFE OPTION FOR STROKE PREVENTION OR JUST A PIPE DREAM?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.10 NEUROLOGIC DISORDERS AND HEART DISEASE

- PO 167 PREDICTORS AND OUTCOMES OF AMYLOID CARDIOMYOPATHY CAUSED BY TRANSTHYRETIN V30 MUTATION

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER

- CO 46 CLINICAL OUTCOMES OF TAVI IN PATIENTS WITH ACTIVE CANCER - A BRIDGE TO SUCCESS?

- PO 239** THE HIGH HDL CONTROVERSY CONTINUES: THE PROGNOSIS FOR WOMEN WITH A HIGH HDL PROFILE IS SERIOUSLY UNFAVOURABLE
- PO 312** THE BURDEN OF MYOCARDIAL INJURY: UNVEILING PREDICTORS OF MORTALITY FROM HOSPITAL TO LONG-TERM OUTCOMES

L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY -> 31.1 CARDIOVASCULAR PHARMACOTHERAPY

- CO 49** META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON THE EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN LEFT VENTRICULAR THROMBOSIS: AN UPDATED PERSPECTIVE
- PO 61** GLP1 AGONISTS: PRESCRIBER INERTIA OR ACCESSIBILITY ISSUE?
- PO 171** THE EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS COMPARED TO WARFARIN FOR LV THROMBUS RESOLUTION
- PO 172** ASSESSING THE BEST ANTICOAGULATION STRATEGY FOR LEFT VENTRICLE THROMBUS AFTER ANTERIOR MYOCARDIAL INFARCTION
- PO 183** SEMAGLUTIDE AND ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY -> 31.5 PHARMACOLOGY AND PHARMACOTHERAPY - OTHER

- PO 77** ANTHRACYCLINE CHEMOTHERAPY: IMPACT ON CARDIAC BIOMARKERS AND FITNESS

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER

- PO 20** FUNCTIONAL CAPACITY ASSESSMENT FOR TAFAMIDIS TREATMENT IN CARDIAC AMYLOIDOSIS PATIENTS
- PO 157** ASSESSMENT OF BALANCE AND PHYSICAL CONDITION AS MEASURES: EVALUATE EFFECTIVENESS OF A CARDIAC REHABILITATION PROGRAMME IN IMPROVING CARDIAC FUNCTION AND FUNCTIONAL CAPACITY.

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.1 IMAGE PROCESSING AND IMAGING STANDARDS

- CO 94** CALCIUM IDENTIFICATION AND SCORING BASED ON 3D TRANSESOPHAGEAL ECHOCARDIOGRAPHY - AN EXPLORATORY STUDY ON AORTIC VALVE STENOSIS

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.2 CARDIOVASCULAR SIGNAL PROCESSING PIC L

- PO 149** ARTIFICIAL INTELLIGENCE-DRIVEN PHONOCARDIOGRAM ANALYSIS FOR NONINVASIVE DETECTION OF PULMONARY HYPERTENSION

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.3 COMPUTER MODELING AND SIMULATION

- CO 74** IMPROVING PACEMAKER IMPLANTATION PREDICTION AFTER TAVR: CREATION AND VALIDATION OF A MACHINE LEARNING BASED MODEL

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH

- PO 24** TRANSFORMING MULTIMODAL STETHOSCOPE SIGNAL QUALITY: THE ROLE OF OPERATOR TRAINING AND FEEDBACK IN ECG AND PCG CLARITY

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.1 PUBLIC HEALTH

- CO 14** TRENDS IN CARDIOVASCULAR HOSPITAL ADMISSIONS OVER THE LAST 15 YEARS: IS IT TIME TO RETHINK HEALTHCARE POLICIES?
- PO 168** TRAINING ON A BUDGET: INDUSTRY SPONSORSHIPS IN CARDIOLOGY RESIDENCY

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.3 HEALTH ECONOMICS

- CO 15** MORTALITY AND HOSPITALIZATION COSTS DUE TO HEART FAILURE ASSOCIATED WITH SYSTEMIC ARTERIAL HYPERTENSION IN BRAZIL FROM 2010 TO 2019
- CO 55** REDUCING THE BURDEN OF ADVANCED HEART FAILURE: A CLINICAL AND ECONOMICAL ANALYSIS OF AN INTERMITTENT LEVOSIMENDAN PROGRAMME
- PO 148** ANÁLISE CUSTO-EFETIVIDADE DA ANGIOPLASTIA PULMONAR SOB TERAPÊUTICA VASODILATADORA PULMONAR VERSUS TERAPÊUTICA VASODILATADORA PULMONAR ISOLADA EM DOENTES COM HPTEC
- PO 169** CARDIOLOGY IN DECLINE: UNVEILING THE DOWNWARD TREND IN RESIDENT PREFERENCES
- PO 170** THE FIRST YEAR OF GENERIC NOACS: IMPLICATIONS FOR PATIENTS AND THE HEALTHCARE SYSTEM
- PO 237** COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT MODEL OF LIPOPROTEIN (A) TESTING IN PORTUGUESE PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN SECONDARY PREVENTION

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.2 BASIC SCIENCE - CARDIAC BIOLOGY AND PHYSIOLOGY

- CO 5** INVESTIGATING THE EFFECTS OF 5 α -ESTRADIOL ON HUMAN MICROVASCULAR ENDOTHELIAL CELLS: A FOCUS ON SEX DIFFERENCES IN CARDIAC HEALTH

P. OTHER -> 37. MISCELLANEA

- CO 71** COULD CHATGPT BE A CARDIOLOGY RESIDENT IN PORTUGAL?